Jenny Ahlstrom on the Importance of Telehealth Waivers for Patients with Cancer

Video

Ahlstrom explained the necessity of offering patients with cancer telehealth opportunities and what patients with cancer will lose should telehealth waivers expire.

The coronavirus disease 2019 (COVID-19) pandemic has led to major systemic changes within health care, including the advent of telehealth.

For patients with cancer, telehealth waivers have represented the removal of geographic limitations, affording patients access to specialists they may have not otherwise easily accessed. However, with some telehealth waivers expiring, even with signs pointing to another possible COVID-19 surge, providers may no longer be able to accommodate telehealth visits.

In an interview with CancerNetwork®, Jenny Ahlstrom, the founder of CrowdCare, discussed the need for telehealth waivers and what her own experience as a patient with cancer has taught her about the importance of telehealth.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Related Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.
Related Content
Eran Ben-Ayre, MD, Discusses Society of Integrative Oncology Recommendations for Telehealth Consultation

Eran Ben-Ayre, MD, Discusses Society of Integrative Oncology Recommendations for Telehealth Consultation

March 13th 2022
Article

In an interview with CancerNetwork®, Eran Ben-Ayre, MD, spoke about guidelines for clinicians treating patients by way of telehealth during the pandemic, and how they can be adapted for future practices.

CancerNetwork® spoke with Debra Patt, MD, PhD, MBA, about the role of telehealth in caring for patients with cancer during the COVID-19 pandemic and beyond.

Oncology Peer Review On-The-Go: Debra Patt, MD, PhD, MBA, on Telehealth in Cancer Care

October 26th 2021
Podcast

CancerNetwork® spoke with Debra Patt, MD, PhD, MBA, about the role of telehealth in caring for patients with cancer during the COVID-19 pandemic and beyond.

Don Dizon, MD, spotlights the daunting experiences lesbian, gay, bisexual, and transgender patients with cancer face, tracing that experience from diagnosis throughout treatment and continuing into symptom management.

Don Dizon, MD on the Experiences of Gay and Transgender Patients With Cancer

November 22nd 2021
Article

Don Dizon, MD, spotlights the daunting experiences lesbian, gay, bisexual, and transgender patients with cancer face, tracing that experience from diagnosis throughout treatment and continuing into symptom management.

Currently, it is not known whether cisgender and transgender patients with cancer respond similarly to standard-of-care therapies due to challenges collecting gender identity and sexual orientation data in clinical cancer research.

Don Dizon, MD on Challenges in Collecting Gender Identity and Sexual Orientation Data in Clinical Cancer Research

November 20th 2021
Article

Currently, it is not known whether cisgender and transgender patients with cancer respond similarly to standard-of-care therapies due to challenges collecting gender identity and sexual orientation data in clinical cancer research.

Don Dizon, MD, emphasizes the importance of policies ensuring higher levels of gay and transgender participation in clinical cancer trials.

Don Dizon, MD on Overcoming Barriers to LGBTQ+ Inclusivity in Clinical Cancer Research

November 19th 2021
Article

Don Dizon, MD, emphasizes the importance of policies ensuring higher levels of gay and transgender participation in clinical cancer trials.

Judd Moul, MD, Reviews Studies From 2021 ASCO Showing Systemic Therapy Advancements in Prostate Cancer

Judd Moul, MD, Reviews Studies From 2021 ASCO Showing Systemic Therapy Advancements in Prostate Cancer

July 29th 2021
Article

Judd Moul, MD, discusses the gravity of new data on systemic therapies for men with castration-resistant prostate cancer and how they can be of use during the COVID-19 pandemic.